The evaluation of studies involving chemotherapeutic protocols for breast cancer therapy indicates that many xenobiotic metabolizing enzymes other than CYP2D6 are also being considered as possible pharmacogenetic targets. The gene discussed is CYP2D6; the disease is breast carcinoma.